Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 5/20 | 1.00 |
| ▸ | FES | P07332 | 3/20 | 0.74 |
| ▸ | FLT3 | P36888 | 3/20 | 0.74 |
| ▸ | DCLK1 | O15075 | 2/20 | 0.71 |
| ▸ | ALK | Q9UM73 | 14/20 | 0.66 |
| ▸ | GAK | O14976 | 3/20 | 0.62 |
| ▸ | INSR | P06213 | 3/20 | 0.62 |
| ▸ | IGF1R | P08069 | 3/20 | 0.62 |
| ▸ | LTK | P29376 | 3/20 | 0.62 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.62 |
| ▸ | TNK2 | Q07912 | 3/20 | 0.62 |
| ▸ | TNK1 | Q13470 | 3/20 | 0.62 |
| ▸ | PTK2B | Q14289 | 3/20 | 0.62 |
| ▸ | ZAP70 | P43403 | 2/20 | 0.62 |
| ▸ | INSRR | P14616 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | CLK1 | P49759 | 2/20 | 0.62 |
| ▸ | BMPR1B | O00238 | 2/20 | 0.61 |
| ▸ | PLK4 | O00444 | 2/20 | 0.61 |
| ▸ | ERN1 | O75460 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18018796 | 0.89 | TTK (0.80) | TTKFESFLT3DCLK1ALK | |
| SCHEMBL3954048 | 0.85 | FES (1.00) | TTKFESFLT3DCLK1ALK | |
| SCHEMBL17731666 | 0.85 | TTK (1.00) | TTKFESFLT3DCLK1ALK | |
| SCHEMBL3959324 | 0.85 | TTK (0.74) | TTKFESFLT3DCLK1ALK | |
| SCHEMBL14866359 | 0.85 | TTK (0.81) | TTKFESFLT3DCLK1ALK | |
| SCHEMBL14866370 | 0.84 | ALK (0.80) | TTKFESFLT3DCLK1ALK | |
| SCHEMBL18018799 | 0.83 | TTK (0.70) | TTKFESFLT3DCLK1ALK | |
| SCHEMBL19867365 | 0.82 | ALK (0.84) | TTKFESFLT3DCLK1ALK | |
| SCHEMBL14866207 | 0.82 | ALK (0.84) | TTKFESFLT3DCLK1ALK | |
| SCHEMBL17731758 | 0.82 | TTK (0.75) | TTKFESFLT3DCLK1ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025101836-A1 | METHOD FOR INDUCING ANEUPLOIDY AND/OR CHROMOSOMAL INSTABILITY IN HUMAN OR NON-HUMAN PRIMATE PLURIPOTENT STEM CELLS AND DIAGNOSTIC/THERAPEUTIC USES THEREOF | THE TRUSTEES OF DARTMOUTH COLLEGE (US) | 2025-05-15 | — | — | WO | claimed |
| EP-4527946-A1 | METHOD FOR PREDICTING THE RESPONSE TO A DUAL SPECIFICITY PROTEIN KINASE TTK INHIBITOR THERAPY | Pangaea Oncology, S.A (ES) | 2025-03-26 | — | — | EP | claimed |
| WO-2023233148-A1 | CANCER THERAPY | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL, (GB) | 2023-12-07 | — | — | WO | claimed |
| US-20250295686-A1 | COMBINATION DECITABINE AND MPS1 INHIBITOR THERAPY TO PRIME CANCER IMMUNOGENICITY | DANA-FARBER CANCER INSTITUTE, INC. | 2025-09-25 | — | — | US | disclosed |
| WO-2025101836-A1 | METHOD FOR INDUCING ANEUPLOIDY AND/OR CHROMOSOMAL INSTABILITY IN HUMAN OR NON-HUMAN PRIMATE PLURIPOTENT STEM CELLS AND DIAGNOSTIC/THERAPEUTIC USES THEREOF | THE TRUSTEES OF DARTMOUTH COLLEGE (US) | 2025-05-15 | — | — | WO | disclosed |
| EP-4527946-A1 | METHOD FOR PREDICTING THE RESPONSE TO A DUAL SPECIFICITY PROTEIN KINASE TTK INHIBITOR THERAPY | Pangaea Oncology, S.A (ES) | 2025-03-26 | — | — | EP | disclosed |
| EP-4419209-A1 | COMBINATION DECITABINE AND MPS1 INHIBITOR THERAPY TO PRIME CANCER IMMUNOGENICITY | Dana-Farber Cancer Institute, Inc. (US) | 2024-08-28 | — | — | EP | disclosed |
| WO-2023243971-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DEMYELINATING DISEASE, COMPRISING KINASE INHIBITOR AS ACTIVE INGREDIENT | 고려대학교 산학협력단 | 2023-12-21 | — | — | WO | disclosed |
| WO-2023233148-A1 | CANCER THERAPY | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL, (GB) | 2023-12-07 | — | — | WO | disclosed |
| WO-2023069943-A1 | COMBINATION DECITABINE AND MPS1 INHIBITOR THERAPY TO PRIME CANCER IMMUNOGENICITY | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-04-27 | — | — | WO | disclosed |